Last reviewed · How we verify
Sedoanalgesia
Sedoanalgesia is a Small molecule drug developed by Elazıg Fethi Sekin Sehir Hastanesi. It is currently in Phase 2 development.
Sedoanalgesia is a medical practice that combines sedation with local anesthesia, typically used in surgical procedures. It has been shown to be cost- and time-effective compared to general or regional anesthesia, reducing the need for nursing staff, anesthetists, and equipment.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sedoanalgesia |
|---|---|
| Sponsor | Elazıg Fethi Sekin Sehir Hastanesi |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- High-Flow Nasal Oxygen vs. Face Mask During Sedoanalgesia in Non-Intubated Thoracoscopic Pericardial Window Surgery (NA)
- Anesthesia Technique and Outcomes in Mechanical Thrombectomy for Acute Ischemic Stroke
- Effects of Patients' Hormone Levels on Sedoanalgesia
- Lullaby vs White Noise vs Silence in Pediatric MRI Sedation (NA)
- Target-Controlled Infusion and Postoperative Neurocognitive Outcomes in Geriatric Patients
- Effects of Different Sedation Techniques on Early Cognitive Recovery After Ambulatory Gynecologic Surgery (NA)
- Pre-Sedation Fluid Replacement and Duodenal Passage Effects on Intraocular Pressure
- Transcatheter Aortic Valve Implantation: Comparison of the Effects of Ultrasound-Guided Pericapsular Nerve Group Block and Fascia Iliaca Block on Postoperative Analgesia Management (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sedoanalgesia CI brief — competitive landscape report
- Sedoanalgesia updates RSS · CI watch RSS
- Elazıg Fethi Sekin Sehir Hastanesi portfolio CI
Frequently asked questions about Sedoanalgesia
What is Sedoanalgesia?
Who makes Sedoanalgesia?
What development phase is Sedoanalgesia in?
Related
- Manufacturer: Elazıg Fethi Sekin Sehir Hastanesi — full pipeline
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing